Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

47.97 +0.14 (+0.29%)
Streaming Delayed Price Updated: 11:07 AM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
39 40 Next >
News headline image
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff ↗
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
Via Benzinga
News headline image
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now? 
Via MarketBeat
News headline image
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences ↗
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease. 
Via Benzinga
News headline image
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval ↗
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. Sarclisa is the... 
Via Benzinga
News headline image
NASDAQ:SNY may be ready to breakout. ↗
Will SANOFI-ADR breakout? 
Via Chartmill
News headline image
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices ↗
FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access... 
Via Benzinga
Topics Lawsuit
News headline image
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows ↗
Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed... 
Via Benzinga
News headline image
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years ↗
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from... 
Via Benzinga
News headline image
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Time To Invest And Or Trade In Bio-Tech Stocks? ↗
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
News headline image
Should You Buy Novavax Stock After This Regulatory Win? ↗
The biotech continues to earn important wins, but is it enough? 
Via The Motley Fool
News headline image
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
News headline image
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease ↗
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints. 
Via Benzinga
News headline image
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Despite its impressive fundamentals, NASDAQ:SNY remains undervalued. ↗
When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
News headline image
Why Sanofi Stock Was Robustly Healthy Today ↗
Investors found something to like about the company's recent round of clinical trials for a key pipeline medication. 
Via The Motley Fool
News headline image
Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials ↗
Sanofi's phase 3 HERCULES study data shows tolebrutinib met the primary endpoint in delaying disability progression in non-relapsing secondary progressive multiple sclerosis. 
Via Benzinga
News headline image
European Stocks Little Moved On Labor Day, German DAX Mark Record Close, Natural Gas Futures Rise: What's Driving Markets Monday? ↗
Global markets started September cautiously, with thin trading volumes as U.S. stock markets were closed for the Labor Day holiday. 
Via Benzinga
Topics Energy
News headline image
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates ↗
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited... 
Via Benzinga
News headline image
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy? ↗
Don't be too quick to jump on the Wall Street bandwagon. 
Via The Motley Fool
News headline image
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst ↗
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and... 
Via Benzinga
News headline image
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell? ↗
Its 12-month relative strength performance is impressive, but Novavax now faces resistance. 
Via Investor's Business Daily
News headline image
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying. ↗
SANOFI-ADR (NASDAQ:SNY) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
News headline image
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk ↗
A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting... 
Via Benzinga
News headline image
3 Biotech Stocks to Buy on the Dip: August 2024 ↗
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning. 
Via InvestorPlace
News headline image
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering ↗
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis. 
Via Investor's Business Daily
News headline image
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. 
Via MarketBeat
News headline image
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment ↗
FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.